Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

PARIS, October 20, 2011 /PRNewswire/ --

- New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress -

- U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS -

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization. A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.

The companies also announced today that the U.S. Food and Drug Administration has accepted for review Sanofi's new drug application (NDA) for oral teriflunomide as a potential therapy for people with relapsing forms of multiple sclerosis (MS).  Sanofi expects to file an application for regulatory approval with the European Medicines Agency (EMA) in the first quarter of 2012.

"The new results of the TEMSO study show that both 7mg and 14mg doses of teriflunomide could reduce the severity of relapses measured through annual rates of relapses leading to hospitalization as well as deliver encouraging long-term results on safety and efficacy," said Professor Paul O'Connor, Director of the MS Clinic at St. Michael's Hospital, Toronto, Canada, and principal investigator of the TEMSO study.

New post-hoc analyses showed that teriflunomide-treated patients' annualize
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Research and Markets has announced ... , Research Area & by End User - Global ... In this report, the global epigenetics market ... and end users. The product segments of the epigenetics ... consumables, kits, and reagents. The subsegments of the enzymes ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... 22, 2014 WriteResult, LLC – ... has been working with a team of researchers from ... Farms Community Farming Collaborative to provide electronic questionnaire data ... The study, which started in May, aims to evaluate ... participants weekly exposure to and participation in urban agriculture ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... "Most Innovative" award by the Association of ... Chinese Canadian Entrepreneurs, ... a biotechnology company discovering and developing the next wave of,antibody ... Executive Officer, received the "Most Innovative" award at the,Chinese Canadian ...
... chemotherapy would welcome an advance promising to dramatically reduce ... researchers at Washington University School of Medicine in St. ... , The researchers focused a powerful drug directly on ... a drug dose 1,000 times lower than used previously ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage ... and inflammatory diseases, today,announced that on April 4, ... Qualifications Department of the NASDAQ Stock Market, LLC. ... "Minimum Bid,Price Requirement," stated that the Company,s common ...
Cached Biology Technology:ARIUS recognized for entrepreneurial excellence 2Nanosized technology has supersized effect on tumors 2Nanosized technology has supersized effect on tumors 3EntreMed Receives Nasdaq Deficiency Notice 2EntreMed Receives Nasdaq Deficiency Notice 3EntreMed Receives Nasdaq Deficiency Notice 4
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market releases photos ... in Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. ... , CEO of NXT-ID thanked his investors and employees "for their ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus ... disease control in many patients, and may also offer the ... Results of a study of 1032 patients with early (less ... after 26 weeks with ADA 40mg every other week + ...
... an economically and environmentally beneficial, ,bio-derived, Australian and ... proposition, according to a report compiled by CSIRO ... players.The report, Flight Path to Sustainable Aviation, predicts ... sustainable, Australia-New Zealand aviation fuels industry could cut ...
... Many kinds of algae and cyanobacteria, common water-dwelling microorganisms, ... water molecules and release hydrogen, which holds promise as ... reason this approach hasn,t yet been harnessed for fuel ... a back seat to the production of compounds that ...
Cached Biology News:Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA 2Sustainable 'bio-derived' jet fuel industry is achievable 2MIT: Teaching algae to make fuel 2
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
... StatMatic I provides a convenient and affordable ... work. Used with an eight-port disposable manifold, ... possible with multi-channel pipettes. The eight-port manifold, ... volumes of 100, 200, 250, or 300mL ...
... Stabilizing Diluent (MOPS Buffered) has been developed ... conjugates in solution. HRP Stabilizer prevents ... the conformation of the antibody or protein ... is filtered at 0.2 microns., ,Contents: ...
384 Well PCR Plate Carrier for Thermo-Sealer...
Biology Products: